ABOS
NASDAQ · Biotechnology
Acumen Pharmaceuticals Inc
$2.36
+0.17 (+7.76%)
Open$2.19
Previous Close$2.19
Day High$2.42
Day Low$2.19
52W High$3.60
52W Low$0.86
Volume—
Avg Volume1.45M
Market Cap154.46M
P/E Ratio—
EPS$-2.21
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+841.5% upside
Current
$2.36
$2.36
Target
$22.22
$22.22
$18.81
$22.22 avg
$35.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 32.13M | 32.40M | 26.28M |
| Net Income | 3.79M | 3.97M | 2.79M |
| Profit Margin | 11.8% | 12.2% | 10.6% |
| EBITDA | 5.50M | 6.39M | 4.32M |
| Free Cash Flow | 1.86M | 2.43M | 2.61M |
| Rev Growth | +20.9% | +8.5% | +2.1% |
| Debt/Equity | 0.36 | 0.35 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |